Waldencast Reports Q4 2025 and FY 2025 Financial Results: Flat Net Revenue, Adjusted EBITDA Growth for Obagi Medical and Milk Makeup.

viernes, 13 de marzo de 2026, 6:58 am ET1 min de lectura
WALD--

Waldencast reported FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million. Q4 2025 net revenue was $72.0 million, flat to Q4 2024, with Adjusted EBITDA of $6.6 million. Obagi Medical saw revenue acceleration, while Milk Makeup maintained US consumption growth through distribution expansion. The company advanced its strategic priorities in 2025, entering medical aesthetics and strengthening its financial flexibility.

Waldencast Reports Q4 2025 and FY 2025 Financial Results: Flat Net Revenue, Adjusted EBITDA Growth for Obagi Medical and Milk Makeup.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios